全文获取类型
收费全文 | 1095篇 |
免费 | 52篇 |
国内免费 | 5篇 |
专业分类
儿科学 | 52篇 |
妇产科学 | 17篇 |
基础医学 | 130篇 |
口腔科学 | 6篇 |
临床医学 | 60篇 |
内科学 | 331篇 |
皮肤病学 | 32篇 |
神经病学 | 29篇 |
特种医学 | 108篇 |
外科学 | 143篇 |
综合类 | 5篇 |
预防医学 | 68篇 |
眼科学 | 18篇 |
药学 | 51篇 |
肿瘤学 | 102篇 |
出版年
2023年 | 6篇 |
2022年 | 14篇 |
2021年 | 32篇 |
2020年 | 14篇 |
2019年 | 31篇 |
2018年 | 31篇 |
2017年 | 31篇 |
2016年 | 24篇 |
2015年 | 24篇 |
2014年 | 63篇 |
2013年 | 53篇 |
2012年 | 69篇 |
2011年 | 89篇 |
2010年 | 43篇 |
2009年 | 52篇 |
2008年 | 65篇 |
2007年 | 57篇 |
2006年 | 66篇 |
2005年 | 59篇 |
2004年 | 50篇 |
2003年 | 35篇 |
2002年 | 41篇 |
2001年 | 28篇 |
2000年 | 24篇 |
1999年 | 18篇 |
1998年 | 10篇 |
1997年 | 9篇 |
1996年 | 11篇 |
1995年 | 10篇 |
1994年 | 3篇 |
1993年 | 3篇 |
1992年 | 9篇 |
1991年 | 4篇 |
1990年 | 8篇 |
1989年 | 4篇 |
1988年 | 5篇 |
1987年 | 5篇 |
1986年 | 5篇 |
1985年 | 5篇 |
1984年 | 3篇 |
1983年 | 3篇 |
1980年 | 2篇 |
1979年 | 4篇 |
1974年 | 4篇 |
1973年 | 7篇 |
1972年 | 1篇 |
1971年 | 4篇 |
1970年 | 2篇 |
1969年 | 5篇 |
1968年 | 4篇 |
排序方式: 共有1152条查询结果,搜索用时 29 毫秒
71.
Martinez-Lostao L Briones J Martinez-Gallo M Forné I Sierra J Rodriguez-Sanchez JL Juarez C 《Leukemia & lymphoma》2004,45(11):2307-2314
B-cell chronic lymphocytic leukemia (B-CLL) is a hematological malignancy characterized by the accumulation of mature CD5+ B lymphocytes with a defective apoptosis. A subset of blood monocyte-derived adherent cells generated in vitro protects B-CLL cells from apoptosis playing a role as nurse-like cells (NLCs). Fludarabine (9-beta-D-arabinofuranosyl-2-fluoroadenine; F-ara-A) is an adenine nucleoside analog used to treat B-CLL. To gain insight into the mechanisms implicated in the antitumoral effect of fludarabine in B-CLL cells, we performed cross-cultures with B-CLL cells and NLCs treated and untreated with fludarabine. Our results showed that fludarabine blocked the development of NLCs and induced apoptosis in these cells when they were present in culture. Moreover, CD19+/CD5+B-CLL cells treated with fludarabine underwent apoptosis and this event was not related with the presence of NLCs whether treated or not with fludarabine. In conclusion, apoptosis induced by fludarabine in CD19+/CD5+B-CLL cells was due to a direct effect on these cells and not due to its effect in the NLCs. 相似文献
72.
73.
Patients with systemic mastocytosis present symptoms related to the tissue response to the release of mediators from mast cells and to the local mast cell burden. Such patients often have a history of chronic and acute mediator-related symptoms. Most patients have indolent disease with a good prognosis and a normal life span. Symptoms can include pruritus, flushing, syncope, gastric distress, nausea and vomiting, diarrhea, bone pain and neuropsychiatric symptoms, most of which are controlled by medication. Because there is no current cure for mastocytosis, successful therapeutic interventions rely on the recognition of mediator-related symptoms and their treatment, and established intervention approaches for the relatively uncommon leukemic concomitants. Efforts to link a particular mast cell-derived mediator to some aspect of the symptom complex depend on the known actions of the mediator and the efficacy of target-based interventions. 相似文献
74.
Taha DR Castells S Umpaichitra V Bastian W Banerji MA 《Journal of pediatric endocrinology & metabolism : JPEM》2002,15(1):59-67
The incidence of type 2 diabetes mellitus (DM) in children and adolescents has substantially increased over the past decade. The present study was conducted to evaluate the beta-cell response to intravenous glucagon (a non-glucose secretagogue) in children with type 2 DM. Twenty pediatric patients with type 2 DM were compared to 15 control subjects matched for body mass index and sexual maturation. The patients' ages ranged between 10 and 19 years. The duration of DM ranged from 1 to 5 years. Nine patients were on insulin treatment and 11 were on diet alone (3 patients) or metformin (8 patients). The criteria for type 2 DM were absent islet cell (IA-2) and glutamic acid decarboxylase (GAD65) antibodies and a fasting serum C-peptide level of > or = 0.23 nmol/l. Plasma glucose and serum C-peptide levels were determined in the fasting state and six minutes after an intravenous injection of 1 mg of glucagon. The fasting and stimulated plasma glucose levels and the fasting serum C-peptide levels (1.02 +/- 0.43 vs 0.79 +/- 0.26 nmol/l, p < 0.05) were higher in the patients with DM compared to weight-matched control subjects. While the absolute C-peptide responses to glucagon were not different between the two groups, the stimulated C-peptide to glucose ratios were significantly lower in the patients with DM compared to controls (0.039 +/- 0.026 vs 0.062 +/- 0.033, p < 0.05). Patients with DM treated with diet or oral therapy had significantly greater basal and stimulated C-peptide concentrations, incremental C-peptide, and C-peptide to glucose ratios than patients on insulin treatment. Both the fasting and the stimulated C-peptide levels were inversely correlated with the duration of DM (r = -0.53, p < 0.05). HbA1c at one year follow-up was inversely correlated with glucagon-stimulated C-peptide levels at the time of the study (r = -0.658, p < 0.01) and positively correlated with the duration of diabetes (r = 0.671, p = 0.002). The apparently normal serum C-peptide levels measured after glucagon challenge in these children with type 2 DM reflect their higher glucose levels. The lower stimulated C-peptide to glucose ratios in these children with type 2 DM compared to normal controls demonstrate their diminished beta-cell response to intravenous glucagon, a non-glucose secretagogue. Among the patients with DM, a higher glucagon-stimulated serum C-peptide response was associated with diet/metformin treatment, a shorter duration of DM and predicted improved glycemic control up to one year later. Thus, the fasting and glucagon-stimulated serum C-peptide levels provide an estimate of the potential insulin secretory capacity of the beta-cell and may predict glycemic control in pediatric type 2 DM. 相似文献
75.
Aguilar Ruiz A Torramilans Lluis A Castells Esteve M Vargas Blasco C 《Actas urologicas espa?olas》2003,27(9):718-720
We present a new case of multilocular cystic nephroma, and a review of literature. If C.T. diagnoses a cystic disease we apply the Bosniak classification. Multilocular cystic nephroma appears as a cystic disease, separately fibrous thin walls, with or without calcifications. We have to make a distinctive diagnosis between RCC and multilocular. Definitive diagnosis is always histological. 相似文献
76.
77.
Non-invasive in vivo imaging of myocardial apoptosis and necrosis 总被引:14,自引:4,他引:10
Myocardial necrosis plays an important role in the pathogenesis of various cardiovascular disorders and can result from different myocardial insults. Its non-invasive identification and localisation therefore may help in the diagnosis of these disorders, as well as in prognosis and assessment of treatment response. Apoptosis, or programmed cell death, is important in the spectrum of myocardial damage since it is gradually becoming more apparent that cell death may begin as apoptosis and not as necrosis. First attempts to directly visualise the area of myocardial necrosis were based on recognition of myocardial infarction with "hot spot imaging agents" in patients with chest pain. Since then, the study of myocardial necrosis with gamma imaging agents has gone beyond the detection of myocardial infarction, and attempts have been made to diagnose other cardiovascular disorders associated with cardiac cell death such as heart transplant rejection, myocarditis, cardiotoxicity and cardiomyopathies. Traditionally, two hot spot imaging agents have been used for the detection of myocardial necrosis, (99m)Tc-pyrophosphate and (111)In-antimyosin. In addition, preliminary studies have demonstrated promising results with (99m)Tc-glucarate. Recently, (99m)Tc-annexin V has been successfully used for non-invasive gamma imaging of apoptosis after acute myocardial infarction, acute myocardial ischaemia, acute cardiac allograft rejection and malignant intracardiac tumours. This review article focusses on the characteristics of these different myocardial necrotic and apoptotic markers and compares their role in the assessment of myocardial damage. 相似文献
78.
Since the mid-1990s, the introduction of new public hospital payment systems to improve the efficiency of Spanish hospitals within the context of managed competition has been debated. Blended systems, which recognize the importance of the activity performed, as well as the role of the hospital in the public health system, have emerged as the best-matched tools both in risk assignment and in efficiency-economic feasibility dialectic.In this article, the payment method used in Catalonia since 1997 is analyzed and contrasted with that introduced in Andalusia in 1998. The evaluation focuses on the instruments used to incorporate the mixed model in the two different settings. On the one hand, the capacity of diagnosis related groups (DRGs) to define hospital product cost is limited. Furthermore, DRGs require numerous adjustments before introduction into Spain. On the other hand, structural level can be defined through the Grade of Memberships in Catalonia and the Basic Centers in Andalusia.We also analyze the introduction of the different methods into Spain and their adaptation to the Catalan and Andalusian environments. The transition periods seem not to have led to a definitive solution and have served to highlight the fragility of the instruments used and of the use that has been made of them.We conclude that the introduction of new tools to improve hospital efficiency through payment systems was precipitate and, to a certain extent, naive. Public hospital payment systems can be considered to be effective when they manage to allocate resources over a period of time. Ensuring the efficiency of public hospitals implies daily work on the part of each hospital and the information systems generated by regional health systems and will not be achieved through external financial tools poorly adapted to the setting in which they are applied. 相似文献
79.
K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. 总被引:17,自引:0,他引:17
A Castells P Puig J Móra J Boadas L Boix E Urgell M Solé G Capellà F Lluís L Fernández-Cruz S Navarro A Farré 《Journal of clinical oncology》1999,17(2):578-584
PURPOSE: Previous studies have demonstrated the presence of K-ras mutations in the plasma of patients with pancreatic carcinoma. However, the diagnostic utility and the prognostic significance of this finding have never been addressed. PATIENTS AND METHODS: Forty-four consecutive patients with histologically confirmed primary pancreatic ductal adenocarcinoma were included. A control group of 37 patients with chronic pancreatitis, 10 patients with other tumors of the pancreatic area, nine patients with acute pancreatitis, and four healthy volunteers was also included. Plasma DNA was isolated and K-ras codon-12 mutations were analyzed by means of restriction fragment length polymorphism-polymerase chain reaction and single-strand conformation polymorphism techniques. Patients were followed up to establish their clinical outcome. RESULTS: The mutant-type K-ras gene was found in plasma DNA samples of 12 (27%) of 44 patients with pancreatic ductal adenocarcinoma; this finding was related to the tumor stage (P = .05), mainly in the presence of distant metastases (P = .02). In addition, K-ras mutations were detected in the plasma DNA of two (5%) of 37 patients with chronic pancreatitis. In the subset of patients with pancreatic masses, the sensitivity and specificity of plasma K-ras analysis for pancreatic adenocarcinoma were 27% and 100%, respectively. Finally, pancreatic carcinoma patients with the mutant-type K-ras gene in plasma DNA exhibited a shorter survival time than patients with the wild-type gene (P<.005), and plasma K-ras mutations were identified as the only independent prognostic factor (odds ratio, 1.51; 95% confidence interval, 1.02 to 2.23). CONCLUSION: Plasma K-ras analysis is a highly specific, low-sensitivity approach that has diagnostic and prognostic clinical implications in patients with pancreatic carcinoma. 相似文献
80.